Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Talecris Biotherapeutics Inc.

Division of Grifols SA
www.talecris.com

Latest From Talecris Biotherapeutics Inc.

CNS IPOs Follow Broad Industry Trends

Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.

BioPharmaceutical Deals

Novartis Trims Its Sails, Divests Blood-Testing Unit To Spain’s Grifols

CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.

Medical Device Europe

Analysts Mixed As Australia’s CSL Moves To Settle U.S. Price Fixing Case

Australia’s CSL has probably made the right decision to settle a price-fixing lawsuit in the United States and thereby avoid a protracted legal battle that could have seen further substantial legal costs even if it eventually won. But the proposed settlement has some analysts concerned the legal basis for the lawsuit was thin as it stemmed from regulatory questions raised in a failed industry merger.

BioPharmaceutical Australia

Grifols to begin trial of inhaled alpha1-proteinase inhibitor for CF

Spanish firm Grifols has announced plans to begin a safety trial of a next-generation inhaled formulation of alpha1-proteinase inhibitor later this year. The news follows the decision by the US FDA to grant orphan drug designation to the product for cystic fibrosis in April.

Orthopedics Respiratory
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • NPS BioTherapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Grifols SA
  • Senior Management
  • Lawrence Stern, CEO
    John M Hanson, EVP, CFO
    Steve Petteway, PhD, EVP, R&D
  • Contact Info
  • Talecris Biotherapeutics Inc.
    Phone: (919) 316-6300
    4101 Research Commons
    79 TW Alex. Dr.
    P.O. Box 110526 Research Triangle Park, NC 27709
    USA
UsernamePublicRestriction

Register